Docetaxel / EGFR Cancer Research Results

docx, Docetaxel: Click to Expand ⟱
Features:
Docetaxel, (brand name Taxotere) is a chemotherapy medication used to treat breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.
Docetaxel is a microtubule-stabilizing agent (taxane). It binds β-tubulin and promotes microtubule polymerization / prevents depolymerization, causing mitotic arrest (G2/M) and downstream cell death.
Clinically important constraints:
-Neutropenia / febrile neutropenia are major dose-limiting toxicities.
-Premedication with dexamethasone is standard to reduce fluid retention and hypersensitivity reactions.
-Metabolism is mainly CYP3A4, so strong CYP3A4 inhibitors/inducers (and grapefruit) can materially change exposure.


Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization (β-tubulin) → mitotic spindle dysfunction Microtubule dynamics ↓; mitotic progression fails Also impacts normal proliferating cells P, R Core cytotoxic mechanism Taxane class MOA: stabilizes microtubules and blocks depolymerization, disrupting mitosis.
2 Mitotic arrest (G2/M checkpoint pressure) G2/M arrest ↑; proliferation ↓ Bone marrow / GI epithelium vulnerability ↑ R, G Cell-cycle blockade Mitotic arrest is the key phenotype linking microtubule disruption to cell death outcomes.
3 Intrinsic apoptosis (mitochondrial) secondary to mitotic catastrophe Apoptosis ↑ (context); caspase activation ↑ ↔ / tissue injury possible at high exposure G Death execution Cell death often occurs after prolonged mitotic arrest (mitotic catastrophe → apoptosis).
4 Neutropenia / marrow suppression (on-target toxicity) — Neutrophils ↓; febrile neutropenia risk ↑ R, G Dose-limiting toxicity Major clinical constraint; risk increases with dose and interacting drugs.
5 Hypersensitivity reactions — Hypersensitivity risk ↑ (especially early infusions) P, R Acute infusion risk Premedication is used to reduce frequency/severity of hypersensitivity reactions.
6 Fluid retention / capillary leak tendency — Fluid retention ↑ (can be severe) R, G Key non-hematologic toxicity Dexamethasone premedication is standard to reduce incidence and severity.
7 Combination leverage (sensitization with other agents) Synergy reported in multiple regimens Toxicity may ↑ depending on partner drug G Regimen-driven efficacy Docetaxel is commonly used in multi-agent protocols; outcome is regimen- and tumor-type-specific.
8 Pharmacokinetics (CYP3A4 metabolism) Exposure ↑ with strong CYP3A4 inhibitors; ↓ with inducers Exposure shifts → toxicity/efficacy shifts P, R Interaction driver Docetaxel is primarily cleared by CYP3A4; strong inhibitors can raise levels substantially.
9 Grapefruit / intestinal CYP3A4 inhibition (interaction risk) Potential exposure ↑ (context) Potential toxicity ↑ (context) P, R Diet–drug interaction Grapefruit can inhibit intestinal CYP3A4; docetaxel is a CYP3A4 substrate, so avoidance is commonly advised.
10 Parameter dependence (dose/schedule; weekly vs q3wk) Mechanism constant; tolerability differs by schedule Toxicity profile differs by schedule — Translation constraint Clinical outcomes and toxicity balance are schedule-dependent (protocol-specific).
11 ROS generation (secondary to mitotic stress) ROS ↑ (mitochondrial); lipid peroxidation ↑ (reported) Oxidative injury possible R, G Stress amplification ROS increase is secondary to mitotic arrest and mitochondrial dysfunction, not a primary redox drug effect.
12 NRF2 antioxidant response NRF2 ↑ (adaptive; reported in resistant models) Protective antioxidant upshift R, G Resistance mechanism NRF2 activation may reduce docetaxel sensitivity by increasing antioxidant capacity (GSH, NQO1, HO-1).

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (binding and immediate microtubule dynamic suppression begins)
  • R: 30 min–3 hr (mitotic checkpoint engagement; acute infusion effects)
  • G: >3 hr (mitotic catastrophe, apoptosis, tissue-level toxicities)
EGFR, Epidermal Growth Factor Receptor: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-Driver
Type: Oncogene
EGFR (Epidermal growth factor receptor), which belongs to the tyrosine kinase receptor family (RTKs)
Epidermal Growth Factor Receptor (EGFR) is a cell surface protein that plays a crucial role in the regulation of cell growth, survival, proliferation, and differentiation. It is part of the ErbB family of receptors and is activated by binding to its ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α).

-plays a crucial role in regulating cell growth and division.

Many cancers exhibit overexpression of EGFR, which can lead to enhanced signaling and contribute to tumor growth and survival. This overexpression is often associated with aggressive tumor behavior and poor prognosis.
Scientific Papers found: Click to Expand⟱
136- CUR,  docx,    Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
Bcl-2↓, Bcl-xL↓, Mcl-1↓, BAX↑, BID↑, PARP↑, NF-kB↓, CDK1↓, COX2↓, RTK-RAS↓, PI3K/Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, ChemoSen↑,
26- EGCG,  QC,  docx,    Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy
- vitro+vivo, Pca, PC3
BAD↓, cl‑PARP↑, Casp7↑, IκB↓, Ki-67↓, VEGF↓, EGFR↓, FGF↓, TGF-β↓, TNF-α↓, SCF↓, Bax:Bcl2↑, NF-kB↓, chemoP↑, ChemoSen↑, TumVol↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

PI3K/Akt↓, 1,  

Cell Death ⓘ

BAD↓, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   BID↑, 1,   Casp7↑, 1,   Mcl-1↓, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,   RTK-RAS↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   PARP↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

FGF↓, 1,   SCF↓, 1,  

Migration ⓘ

Ki-67↓, 1,   TGF-β↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 2,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IκB↓, 1,   NF-kB↓, 2,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,  

Clinical Biomarkers ⓘ

EGFR↓, 2,   HER2/EBBR2↓, 1,   Ki-67↓, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,   TumVol↓, 1,  
Total Targets: 31

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: EGFR, Epidermal Growth Factor Receptor
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:178  Target#:94  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page